Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed

World Journal of Gastroenterology

Volumn 19, Issue 31, 2013, Pages 5029-5034

  Guarino, Michele Pier Luca ^a   Cocca, Silvia ^a   Altomare, Annamaria ^a   Emerenziani, Sara ^a   Cicala, Michele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cholesterol gallstones; Gallbladder; Ursodeoxycholic acid

Indexed keywords

BILE ACID; CD68 ANTIGEN; CHENODEOXYCHOLIC ACID; CYCLOOXYGENASE 2; PLACEBO; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; URSODEOXYCHOLIC ACID; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; CHOLECYSTECTOMY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EDITORIAL; EXTRACORPOREAL LITHOTRIPSY; FOLLOW UP; GALLBLADDER DISEASE; GALLSTONE; HUMAN; INCIDENCE; LIPID PEROXIDATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENCE RISK; SIDE EFFECT; STONE DISSOLUTION; GALLSTONES; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; GALLSTONES; GASTROINTESTINAL AGENTS; HUMANS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84882259107     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i31.5029     Document Type: Editorial

References (46)

1. Lammert F, Miquel JF. Gallstone disease: from genes to evidence- based therapy. J Hepatol 2008; 48 Suppl 1: S124-S135 [PMID: 18308417 DOI: 10.1016/j.jhep.2008.01.012]
2. Traverso LW. Clinical manifestations and impact of gallstone disease. Am J Surg 1993; 165: 405-409 [PMID: 8480872]
3. Wang DQH, Afdhal NH. Gallstone disease. In: Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Philadelphia: Saunders Elsevier, 2010: 1089-1119
4. Nakeeb A, Comuzzie AG, Martin L, Sonnenberg GE, Swartz-Basile D, Kissebah AH, Pitt HA. Gallstones: genetics versus environment. Ann Surg 2002; 235: 842-849 [PMID: 12035041 DOI: 10.1097/00000658-200206000-00012]
5. Schafmayer C, Tepel J, Franke A, Buch S, Lieb S, Seeger M, Lammert F, Kremer B, Fölsch UR, Fändrich F, Schreiber S, Hampe J. Investigation of the Lith1 candidate genes ABCB11 and LXRA in human gallstone disease. Hepatology 2006; 44: 650-657 [PMID: 16941683 DOI: 10.1002/hep.21289]
6. Tait N, Little JM. The treatment of gall stones. BMJ 1995; 311: 99-105 [PMID: 7613411]
7. Sakorafas GH, Milingos D, Peros G. Asymptomatic cholelithiasis: is cholecystectomy really needed? A critical reappraisal 15 years after the introduction of laparoscopic cholecystectomy. Dig Dis Sci 2007; 52: 1313-1325 [PMID: 17390223 DOI: 10.1007/s10620-006-9107-3]
8. Gallstones and laparoscopic cholecystectomy. NIH Consens Statement 1992; 10: 1-28 [PMID: 1301217]
9. Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg 1993; 165: 399-404 [PMID: 8480871 DOI: 10.1016/S0002-9610(05)80930-4]
10. Howard DE, Fromm H. Nonsurgical management of gallstone disease. Gastroenterol Clin North Am 1999; 28: 133-144 [PMID: 10198782 DOI: 10.1016/S0889-8553(05)70047-9]
11. Ellis RD, Jenkins AP, Thompson RP, Ede RJ. Clearance of refractory bile duct stones with extracorporeal shockwave lithotripsy. Gut 2000; 47: 728-731 [PMID: 11034593 DOI: 10.1136/gut.47.5.728]
12. Vergunst H, Terpstra OT, Brakel K, Laméris JS, van Blankenstein M, Schröder FH. Extracorporeal shockwave lithotripsy of gallstones. Possibilities and limitations. Ann Surg 1989; 210: 565-575 [PMID: 2684058 DOI: 10.1097/00000658-198911000-0 0001]
13. Thistle JL, May GR, Bender CE, Williams HJ, LeRoy AJ, Nelson PE, Peine CJ, Petersen BT, McCullough JE. Dissolution of cholesterol gallbladder stones by methyl tert-butyl ether administered by percutaneous transhepatic catheter. N Engl J Med 1989; 320: 633-639 [PMID: 2918875 DOI: 10.1056/ NEJM198903093201004]
14. Portincasa P, Di Ciaula A, Wang HH, Moschetta A, Wang DQ. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr Med Chem 2009; 16: 1531-1542 [PMID: 19355905 DOI: 10.2174/092986709787909631]
15. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 1972; 286: 1-8 [PMID: 5006919 DOI: 10.1056/ NEJM197201062860101]
16. Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther 2012; 3: 7-20 [PMID: 22577615 DOI: 10.4292/wjgpt.v3.i2.7]
17. Chapman BA, Burt MJ, Chisholm RJ, Allan RB, Yeo KH, Ross AG. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 1998; 43: 349-353 [PMID: 9512129]
18. Zúñiga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, Arrese M, Lammert F, Miquel JF. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008; 28: 935-947 [PMID: 18783541 DOI: 10.1111/ j.1478-3231.2008.01808]
19. Wang HH, Portincasa P, de Bari O, Liu KJ, Garruti G, Neuschwander-Tetri BA, Wang DQ. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Invest 2013; 43: 413-426 [PMID: 23419155 DOI: 10.1111/eci.12058]
20. Hillebrant CG, Nyberg B, Gustafsson U, Sahlin S, Björkhem I, Rudling M, Einarsson C. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Eur J Clin Invest 2002; 32: 528-534 [PMID: 12153554 DOI: 10.1046/j.1365-2362.2002.01015]
21. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008; 134: 2101-2110 [PMID: 18442485 DOI: 10.1053/j.gastro.2008.03.011]
22. Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol 1998; 13: 659-664 [PMID: 9715413 DOI: 10.1111/j.1440-1746.1998.tb00707]
23. Hofmann AF. Herbert Falk: a vital force in the renaissance of bile acid research and bile acid therapy. Dig Dis 2011; 29: 23-36 [PMID: 21691101]
24. Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011; 121: 523-544 [PMID: 21854363 DOI: 10.1042/ CS20110184]
25. Knas M, Dutkiewicz E, Szajda SD, Borzym-Kluczyk M, Lukivskaya O, Dudzik D, Zawadzki P, Zwierz K. Ursodeoxycholic acid-panacea for liver diseases? E&C Hepatology 2006; 2: 12-19
26. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993; 104: 1865-1870 [PMID: 8500748]
27. Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, Shefer S. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982; 97: 351-356 [PMID: 7051912 DOI: 10.7326/0003-4819-97-3-351]
28. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35: 134-146 [PMID: 11495032 DOI: 10.1016/S0168-8278(01)00092-7]
29. Villanova N, Bazzoli F, Taroni F, Frabboni R, Mazzella G, Festi D, Barbara L, Roda E. Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment. Gastroenterology 1989; 97: 726-731 [PMID: 2753332]
30. Tomida S, Abei M, Yamaguchi T, Matsuzaki Y, Shoda J, Tanaka N, Osuga T. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999; 30: 6-13 [PMID: 10385632]
31. Venneman NG, Besselink MG, Keulemans YC, Vanberge- Henegouwen GP, Boermeester MA, Broeders IA, Go PM, van Erpecum KJ. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 2006; 43: 1276-1283 [PMID: 16729326 DOI: 10.1002/hep.21182]
32. Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 2007; 56: 815-820 [PMID: 17185355 DOI: 10.1136/gut.2006.109934]
33. Parkman HP, Bogar LJ, Bartula LL, Pagano AP, Thomas RM, Myers SI. Effect of experimental acalculous cholecystitis on gallbladder smooth muscle contractility. Dig Dis Sci 1999; 44: 2235-2243 [PMID: 10573368]
34. Xiao ZL, Chen Q, Biancani P, Behar J. Abnormalities of gallbladder muscle associated with acute inflammation in guinea pigs. Am J Physiol Gastrointest Liver Physiol 2001; 281: G490-G497 [PMID: 11447029]
35. Strasberg SM. Acute calculous cholecystitis. In: Haubrich WS, Schaffner F, Berk JE. Gastroenterology. Philadelphia: Saunders, 1995: 2635-2664
36. Xiao ZL, Rho AK, Biancani P, Behar J. Effects of bile acids on the muscle functions of guinea pig gallbladder. Am J Physiol Gastrointest Liver Physiol 2002; 283: G87-G94 [PMID: 12065295 DOI: 10.1152/ajpgi.00536.2001]
37. Xiao ZL, Andrada MJ, Biancani P, Behar J. Reactive oxygen species (H(2)O(2)): effects on the gallbladder muscle of guinea pigs. Am J Physiol Gastrointest Liver Physiol 2002; 282: G300-G306 [PMID: 11804851 DOI: 10.1152/ajpgi.00241.2001]
38. van de Heijning BJ, van de Meeberg PC, Portincasa P, Doornewaard H, Hoebers FJ, van Erpecum KJ, Vanberge- Henegouwen GP. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci 1999; 44: 190-196 [PMID: 9952243]
39. Becker S, Reinehr R, Graf D, vom Dahl S, Häussinger D. Hydrophobic bile salts induce hepatocyte shrinkage via NADPH oxidase activation. Cell Physiol Biochem 2007; 19: 89-98 [PMID: 17310103 DOI: 10.1159/000099197]
40. Iwaki T, Ishizaki K, Kinoshita S, Tanaka H, Fukunari A, Tsurufuji M, Imada T. Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters. World J Gastroenterol 2007; 13: 5003-5008 [PMID: 17854144]
41. Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996; 39: 475-478 [PMID: 8949657 DOI: 10.1136/gut.39.3.475]
42. Combes B, Carithers RL, Maddrey WC, Munoz S, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, White H, Zetterman RK, Risser R, Rossi SS, Hofmann AF. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999; 29: 1649-1654 [PMID: 10347103]
43. Guarino MP, Carotti S, Morini S, Perrone G, Behar J, Altomare A, Alloni R, Caviglia R, Emerenziani S, Rabitti C, Cicala M. Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut 2008; 57: 1740-1741 [PMID: 19022933 DOI: 10.1136/gut.2008.160333]
44. Schwarz NT, Kalff JC, Türler A, Engel BM, Watkins SC, Billiar TR, Bauer AJ. Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus. Gastroenterology 2001; 121: 1354-1371 [PMID: 11729115 DOI: 10.1053/ gast.2001.29605]
45. Rebollar E, Arruebo MP, Plaza MA, Murillo MD. Effect of lipopolysaccharide on rabbit small intestine muscle contractility in vitro: role of prostaglandins. Neurogastroenterol Motil 2002; 14: 633-642 [PMID: 12464085 DOI: 10.1046/ j.1365-2982.2002.00364.x]
46. Xiao ZL, Biancani P, Behar J. Role of PGE2 on gallbladder muscle cytoprotection of guinea pigs. Am J Physiol Gastrointest Liver Physiol 2004; 286: G82-G88 [PMID: 12936912 DOI: 10.1152/ajpgi.00247.2003]